Pharmaceutical care of aspirin therapy in a patient with glucose-6-phosphate dehydrogenases deficiency
10.3760/cma.j.cn114015-20200530-00609
- VernacularTitle:葡萄糖-6-磷酸脱氢酶缺乏症患者阿司匹林治疗的药学监护
- Author:
Xiaoli ZHANG
1
;
Zhongjiang ZHOU
;
Ping ZHENG
Author Information
1. 南方医科大学南方医院药学部，广州 510515
- Publication Type:Journal Article
- Keywords:
Glucosephosphate dehydrogenase deficiency;
Diabetes mellitus;
Percutaneous coronary intervention;
Aspirin;
Sulfonylurea compounds
- From:
Adverse Drug Reactions Journal
2021;23(3):145-147
- CountryChina
- Language:Chinese
-
Abstract:
A 63-year-old male patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency and type 2 diabetes mellitus received long-term use of glimepiride (2 mg once daily) and no adverse reactions occurred. He underwent percutaneous coronary intervention (PCI) followed by drug-eluting stent (DES) implantation because of acute inferior myocardial infarction. After the operation, dual antiplatelet therapy with oral aspirin enteric-coated tablets (100 mg once daily) and ticagrelor (90 mg twice daily) was given. Clinical pharmacists participated in the ward round and learned that the patient had a history of G6PD deficiency. After consulting the list of unsafe drugs for G6PD deficiency patients, the pharmacists found that glimepiride and aspirin were high-risk drugs that could induce hemolysis in G6PD deficiency patients. It was believed that the combination of the 2 drugs might increase the patient′s risk of hemolysis. They recommended that glimepiride should be discontinued and routine aspirin after PCI and DES should be continued. The physician adopted the pharmacists′ advice and the hypoglycemic agent was replaced by metformin hydrochloride. The patient recovered soon after surgery. At a 3-month follow-up, no hemolytic reaction occurred in the patient.
